Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Testori

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.
Frontiers in Immunology|February 9, 2026
<i>CMTM8</i> variants influence BNT162b2 COVID-19 vaccination response by regulating granulocytic/polymorphonuclear myeloid-derived suppressor cell activityAlessandro Testori, Antonella Mulas, Mara Marongiu, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2011
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyRiccardo Danielli, Ruggero Ridolfi, Vanna Chiarion-Sileni, et al.
International Journal of Oncology|May 10, 2003
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative GroupPaolo A Ascierto, Giuseppe Palmieri, Gerardo Botti, et al.
The Journal of Clinical Endocrinology and Metabolism|November 17, 2016
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid CancerVincenzo Marotta, Concetta Sciammarella, Mario Capasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Plos One|November 14, 2013
Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in ItalySara Gandini, Esther De Vries, Giulio Tosti, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.
Frontiers in Immunology|February 9, 2026
<i>CMTM8</i> variants influence BNT162b2 COVID-19 vaccination response by regulating granulocytic/polymorphonuclear myeloid-derived suppressor cell activityAlessandro Testori, Antonella Mulas, Mara Marongiu, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2011
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyRiccardo Danielli, Ruggero Ridolfi, Vanna Chiarion-Sileni, et al.
International Journal of Oncology|May 10, 2003
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative GroupPaolo A Ascierto, Giuseppe Palmieri, Gerardo Botti, et al.
The Journal of Clinical Endocrinology and Metabolism|November 17, 2016
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid CancerVincenzo Marotta, Concetta Sciammarella, Mario Capasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Plos One|November 14, 2013
Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in ItalySara Gandini, Esther De Vries, Giulio Tosti, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
Pageof 16